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Abstract
Objective—To present the case of a patient with a history of thyroid cancer, post-surgical
hypoparathyroidism, chronic calcitriol use, and normal renal function who presented with painful
skin lesions secondary to calciphylaxis.
Methods—We describe the history, biochemistry, histopathology, evaluation, and management
of this patient.
Results—A 47 year-old female with hypoparathyroidism, chronically treated with calcitriol and
calcium, presented with exquisitely painful skin ulcerations. Four months prior to the onset of
symptoms, she had initiated warfarin therapy for atrial fibrillation. Review of laboratory data from
the past year revealed elevated calcium and phosphorus levels. A diagnosis of calciphylaxis was
made based upon pathologic evaluation of a skin biopsy. Management included titration of
calcitriol and calcium to maintain serum calcium and phosphate levels in the low normal range.
Sodium thiosulfate was administered at a dose of 25 mg IV three times a week with some
resolution in the patient's pain. Unfortunately, the patient battled recurrent bacteremia and sepsis,
presumably related to her calciphylaxis wounds, and ultimately succumbed to complications from
sepsis.
Conclusion—While calciphylaxis is typically associated with renal insufficiency and secondary
hyperparathyroidism, we highlight the case of a patient with normal renal function and
hypoparathyroidism. Patients treated with chronic calcitriol should have serum calcium and
phosphorus monitored closely and may benefit from non-calcium based phosphate binders if
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hyperphosphatemia becomes unavoidable. This is especially important in the presence of other
risk factors for calciphylaxis including warfarin use.
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Phosphate product
INTRODUCTION
Calciphylaxis, or calcific uremic arteriolopathy, is a rare condition involving calcification
and fibrosis of small and medium sized arterioles that results in painful, necrotic skin lesions
(1). Histologic findings include “clean” necrosis with inflammation over a background of
small and medium sized blood vessel calcification (2). While the prognosis of calciphylaxis
remains guarded given potential complications of digital gangrene, sepsis, pancreatitis, and
multisystem organ failure (2), treatment with sodium thiosulfate has led to successful
resolution in a number of cases. Calciphylaxis has its strongest association with end stage
renal disease; however, a number of other predisposing factors have been identified (Table
1). Moreover, while renal insufficiency was previously felt to be a prerequisite for the
development of calciphylaxis, an increasing number of cases have been reported in persons
with normal renal function (3). There is literature to suggest that primary
hyperparathyroidism as well as treatment with vitamin D analogues, such as calcitriol, in
hypoparathyroidism are associated with calciphylaxis (1, 4-7). New insights into the
molecular pathways that normally act to inhibit tissue calcification have provided an
enhanced understanding of the pathophysiology of how calciphylaxis occurs. Most notably,
protein inhibitors of calcification, such as matrix Gla protein require vitamin K for optimal
activity, providing a molecular explanation for a clinical association with warfarin.
CASE REPORT
We present the case of a 47 year-old female who was transferred from an outside hospital
for management of painful, necrotic, skin lesions. She had a remote history of a complete
thyroidectomy for thyroid cancer resulting in chronic hypoparathyroidism. The patient
required calcitriol and calcium supplementation since her initial surgery > 5 years ago.
Additional evaluation revealed normal renal function, but a BMI of 37 m/kg2, indicating
morbid obesity. Approximately four months prior to presentation, warfarin therapy was
initiated for atrial fibrillation. Biochemical data describing serum calcium and phosphorus
levels were somewhat incomplete due to treatment at different facilities (Table 2). However,
the general trend revealed a rising phosphorus level with serum concentrations as high as 7.4
mg/dL and serum calcium levels as high as 9.5 mg/dL, indicating a calcium phosphate
product of nearly 70.
Based on the clinical history and physical examination, the differential diagnosis included
calciphylaxis, warfarin-induced skin necrosis, antiphospholipid syndrome, cellulitis,
pyoderma gangrenosa, vasculitis, embolic phenomenon, disseminated intravascular
coagulation, connective tissue disease, and peripheral vascular disease (8). To obtain a
definitive diagnosis, the patient went to the operating suite for surgical debridement of her
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abdominal wounds at the outside hospital (Figure 1A-C). The pathology from these
specimens indicated findings consistent with calciphylaxis (Fig 1D-E). Upon transfer to our
facility and because of the recent initiation of warfarin, specimens were obtained from the
outside hospital. Review by a second set of pathologists again indicated a diagnosis of
calciphylaxis, which was based on evidence of soft tissue and focal small vessel
calcification (Fig 1D-E).
Despite surgical debridement, the patient continued to have severe and unrelenting pain
associated with her wounds. In consultation with Nephrology, the patient was started on
sodium thiosulfate at the standard dose of 25 g IV three times a week. While she continued
to have pain, there was some improvement with this intervention. In terms of her calcium
management, an attempt was made to keep her calcium in the range of 7-8 mg/dL and
phosphorus in the range of 3-4 mg/dL. Unfortunately, the patient battled recurrent
bacteremia and sepsis, presumably related to her calciphylaxis wounds, and later succumbed
to complications from sepsis.
DISCUSSION
Calciphylaxis is a profoundly painful, debilitating and sometimes deadly condition that
typically affects patients with chronic kidney disease. The mortality of calciphylaxis
approaches 45-50% and is generally associated with the development of sepsis (1, 3). We
present a case of calciphylaxis in a patient with normal kidney function but other risk factors
including an elevated serum phosphorus related to chronic calcitriol use, warfarin
anticoagulation, obesity, and Caucasian race. Levels of serum calcium and phosphate are
important determinants of calcification, and a calcium phosphate product >70 significantly
increases the risk of developing calciphylaxis (1). However, there is emerging data that
elevations in serum phosphorus play a more central role in the development of calciphylaxis
(4). This may explain why individuals maintained on chronic calcitriol, where
hyperphosphatemia can occur during dose titration, would be prone to the development of
calciphylaxis in the right clinical setting. Nephrologists commonly use phosphate binders to
control phosphate levels in CKD. To our knowledge, phosphate binders are used less
frequently in hypoparathyroid patients with normal renal function. A literature review
revealed only two other cases of calciphylaxis in the setting of hypoparathyroidism, one of
which was associated with preserved renal function and the other with end stage renal
disease (9, 10). Admittedly, this appears to be a rare complication in hypoparathyroid
individuals, however findings from cases such as ours suggest that Endocrinologists should
be aware of this potential complication of calcitriol.
An important risk factor in this patient was the initiation of warfarin anticoagulation. The
mechanism through which warfarin contributes to the development of calciphylaxis is
thought to be related to its interaction with matrix Gla protein (MGP). While MGP normally
inhibits bone morphogenic protein-2 from causing arteriole mineralization, warfarin inhibits
carboxylation of the MGP, leading to its inactivation (5, 11). Additional studies have also
identified a role for α2-Heremans-Schmid glycoprotein (Ahsg) in the inhibition of
calcification. Deficiencies in Ahsg, as is seen in chronic kidney disease and other
inflammatory states, may further contribute to the risk of developing calciphylaxis (12, 13).
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The diagnosis of calciphylaxis is based largely on histologic findings, but there are reports
that three phase bone scan might have diagnostic utility and be useful in monitoring
progression (14). Severe pain is a hallmark of calciphylaxis, and it is historically very
difficult to treat. Several modalities have been reported to improve pain and contribute to
resolution of this condition. Sodium thiosulfate has now been widely used and is thought to
work via multiple mechanisms. First, it may act as antioxidant with resulting vasodilation in
the peripheral vasculature leading to reductions in necrosis and inflammation. More notably,
the administration of sodium thiosulfate results in the production of calcium thiosulfate,
which is thought to pull calcium out of the arterioles and peripheral tissue and allow it to be
eliminated via urinary excretion or dialysis. Up to 2 months of treatment may be required to
see improvement, and it is important to note that the literature supporting the use of sodium
thiosulfate consists of case series and case reports (6, 7, 14, 15). No randomized controlled
studies have been performed. There have also been case reports of resolution of
calciphylaxis with the use of bisphosphonates and cinacalcet (15, 16). The obvious
limitation in the widespread use of bisphosphonates is that many patients with calciphylaxis
also have decreased renal function. Diligent wound care is a must, and hyperbaric oxygen
used alone or in combination with sodium thiosulfate is also thought aid in resolution (6,
15).
CONCLUSION
We present this case for the benefit of the Endocrinology community. Much of the existing
literature describing calciphylaxis has been published in Nephrology and Dermatology
journals. However, the calcitriol label explicitly contains a warning for an elevated calcium
phosphate product as well as the possibility of vascular and soft tissue calcification (17).
Patients treated with chronic calcitriol should have serum calcium and phosphorus
monitored closely and may benefit from the use of non-calcium based phosphate binders if
hyperphosphatemia becomes unavoidable. Also of relevance to Endocrinologists is data to
suggest that primary hyperparathyroidism is the most common non-uremic condition
associated with the development of calciphylaxis (1, 4). These associations are especially
important in our Endocrine patients with other risk factors for calciphylaxis including CKD,
obesity, or warfarin use. Given that calciphylaxis is still very difficult to treat and associated
with high mortality, preventing the development of this condition should be considered
imperative.
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Abbreviations
Ahsg α2-Heremans-Schmid glycoprotein
CKD chronic kidney disease
OR operating room
DIC disseminated intravascular coagulation
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GFR glomerular filtration rate
Ca Calcium
Phos Phosphorus
Ca × Phos calcium phosphorus product
MGP Matrix G1a protein
PTH parathyroid hormone
RANK receptor activator of nuclear factor-κB
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Fig 1.
A-C, Photographs of the patient's abdomen showing violaceous skin with nonhealing ulcers
and underlying tissue necrosis consistent with a calciphylaxis lesion. D-E, High and low
power magnification of biopsy of lesions showing obvious calcification of a blood vessel
and subcutaneous tissue indicative of calciphylaxis (2).
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Table 1
Risk Factors in Developing Calciphylaxis (7)
1. End Stage Renal Disease 5. Caucasian race
2. Hyperparathyroidism 6. Calcium containing phosphate binders
3. Hyperphosphatemia 7. Vitamin D therapy
4. Elevated calcium x phosphate product (>70) 8. Warfarin use
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Table 2
Timeline of presentation including known biochemical values
Date Notes Serum Ca Serum Phos Ca x Phos
7/10/2010 7.6 mg/dL 5.8 mg/dL 44.08
5/16/2012 7.3 mg/dL 4.7 mg/dL 34.31
5/21/2012 Initiation of warfarin
7/30/2012 unknown 6.7 mg/dL Unable to calculate
8/2/2012 unknown 7.4 mg/dL Unable to calculate
8/17/2012 Skin lesions develop
10/2/2012 9.6 mg/dL unknown Unable to calculate
11/24/2012 8.0 mg/dL 5.5 mg/dL 44 mg/dL
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